Association of IL4RA polymorphism in predicting susceptibility toward chronic obstructive pulmonary disease.

IF 1.9 4区医学 Q3 PHARMACOLOGY & PHARMACY

Pharmacogenomics Pub Date : 2023-07-01 Epub Date: 2023-08-08 DOI:10.2217/pgs-2023-0010

Depanshi Pandit, Parul Sharma, Harsh Yadav, Kranti Garg, Vishal Chopra, Siddharth Sharma

{"title":"Association of IL4RA polymorphism in predicting susceptibility toward chronic obstructive pulmonary disease.","authors":"Depanshi Pandit, Parul Sharma, Harsh Yadav, Kranti Garg, Vishal Chopra, Siddharth Sharma","doi":"10.2217/pgs-2023-0010","DOIUrl":null,"url":null,"abstract":"Background: The cytokine IL-4 plays vital role in the intercellular signalling network during immune responses to allergen exposure. Methods: This cross-sectional study involved 202 chronic obstructive pulmonary disease (COPD) patients and 203 healthy individuals. The genotyping of IL4RAQ576R gene polymorphism was determined using PCR restriction fragment length polymorphism analysis. Results: Significant association between mutant genotype (GG) and combined (AA+AG) genotype for the risk of COPD was found (odds ratio [OR]: 4.32; p = 0.04). A significant protective effect was observed between the IL4RAQ576R polymorphism and Global Strategy for Obstructive Lung Disease (GOLD) stage four patients in a recessive model (AA+AG vs GG; p = 0.002). In GOLD A, a substantial relationship was found between the AG and wild-type genotypes (AA) for COPD risk (OR: 2.38; p = 0.03). A strong association was found for COPD duration of 5-10 years (OR: 8.80; p = 0.01). Conclusion: IL4RAQ576R polymorphism is associated with COPD susceptibility.","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/pgs-2023-0010","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/8/8 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The cytokine IL-4 plays vital role in the intercellular signalling network during immune responses to allergen exposure. Methods: This cross-sectional study involved 202 chronic obstructive pulmonary disease (COPD) patients and 203 healthy individuals. The genotyping of IL4RAQ576R gene polymorphism was determined using PCR restriction fragment length polymorphism analysis. Results: Significant association between mutant genotype (GG) and combined (AA+AG) genotype for the risk of COPD was found (odds ratio [OR]: 4.32; p = 0.04). A significant protective effect was observed between the IL4RAQ576R polymorphism and Global Strategy for Obstructive Lung Disease (GOLD) stage four patients in a recessive model (AA+AG vs GG; p = 0.002). In GOLD A, a substantial relationship was found between the AG and wild-type genotypes (AA) for COPD risk (OR: 2.38; p = 0.03). A strong association was found for COPD duration of 5-10 years (OR: 8.80; p = 0.01). Conclusion: IL4RAQ576R polymorphism is associated with COPD susceptibility.

查看原文本刊更多论文

IL4RA多态性与预测慢性阻塞性肺疾病易感性的相关性。

背景：细胞因子IL-4在对过敏原暴露的免疫反应中在细胞间信号网络中起着至关重要的作用。方法：这项横断面研究涉及202名慢性阻塞性肺病（COPD）患者和203名健康人。应用聚合酶链式反应限制性片段长度多态性分析方法对IL4RAK576R基因多态性进行分型。结果：突变基因型（GG）和联合基因型（AA+AG）与COPD风险显著相关（比值比[OR]:4.32；p=0.04）。在隐性模型中，IL4RAK576R多态性与阻塞性肺病全球策略（GOLD）四期患者之间观察到显著的保护作用（AA+AGvs GG；p=0.002）。在GOLD A中，AG基因型和野生型基因型（AA）与COPD危险性有显著相关性（OR:2.38；p=0.03）。COPD持续时间为5-10年（OR:8.80；p=0.01）。结论：IL4RAK576R多态性与COPD易感性有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmacogenomics 医学-药学

CiteScore

3.40

自引率

9.50%

发文量

审稿时长

4-8 weeks

期刊介绍： Pharmacogenomics (ISSN 1462-2416) is a peer-reviewed journal presenting reviews and reports by the researchers and decision-makers closely involved in this rapidly developing area. Key objectives are to provide the community with an essential resource for keeping abreast of the latest developments in all areas of this exciting field. Pharmacogenomics is the leading source of commentary and analysis, bringing you the highest quality expert analyses from corporate and academic opinion leaders in the field.